发明授权
- 专利标题： CXCR2 inhibitors
- 专利标题（中）： CXCR2抑制剂
-
申请号： US13079522申请日： 2011-04-04
-
公开(公告)号： US08283479B2公开(公告)日： 2012-10-09
- 发明人: Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, Jr. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
- 申请人： Stephanie Hachtel , Juergen Dedio , Holger Heitsch , Werngard Czechtizky , Sven Grueneberg , Stephen J. Shimshock , Raymond W. Kosley, Jr. , Carolina L. Lanter , Hui Li , Rosy Sher , Aleksandra Weichsel
- 申请人地址： DE Frankfurt am Main
- 专利权人： Sanofi-Aventis Deutschland GmbH
- 当前专利权人： Sanofi-Aventis Deutschland GmbH
- 当前专利权人地址： DE Frankfurt am Main
- 代理机构： Scully, Scott, Murphy & Presser, P.C.
- 优先权： EP04031009 20041230
- 主分类号： C07D333/66
- IPC分类号： C07D333/66 ; C07D409/12 ; A61K31/44
摘要：
The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
公开/授权文献
- US20110184177A1 CXCR2 INHIBITORS 公开/授权日：2011-07-28
信息查询
